SCHEMBL7249247

SCHEMBL7249247

O=C1c2ccc(Br)cc2COc2ccc(O)cc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.69
MAPT P10636 3/20 0.69
RAB9A P51151 2/20 0.69
APP P05067 10/20 0.56
BCL2 P10415 1/20 0.45
MCL1 Q07820 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
ESR1 P03372 1/20 0.43
UGT1A1 P22309 1/20 0.43
ESR2 Q92731 1/20 0.43
METAP1 P53582 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1919447 0.83 APP (0.47) ALDH1A1MAPTRAB9AAPPTDP1
SCHEMBL7806842 0.83 MAPT (0.69) ALDH1A1MAPTRAB9AAPPTDP1
Phenol SCHEMBL9561887 0.82 MAPT (0.57) ALDH1A1MAPTRAB9AAPPTDP1
SCHEMBL3142640 0.82 MAPT (0.72) ALDH1A1MAPTRAB9AAPPTDP1
SCHEMBL655741 0.82 MAPT (1.00) ALDH1A1MAPTRAB9ATDP1SMN1; SMN2
SCHEMBL9129183 0.82 MAPT (0.58) ALDH1A1MAPTRAB9AAPPTDP1
SCHEMBL1918267 0.81 MAPK14 (0.55) ALDH1A1MAPTRAB9AAPPTDP1
SCHEMBL7808175 0.81 MAPT (0.69) ALDH1A1MAPTRAB9AAPPTDP1
SCHEMBL7913164 0.81 ALDH1A1 (0.69) ALDH1A1MAPTRAB9AAPPTDP1
SCHEMBL7809527 0.80 MAPT (0.64) ALDH1A1MAPTRAB9AAPPTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216571-A1 Antiallergens; antiinflammatory agents UBE INDUSTRIES, LTD. (JP) 2003-11-20 US disclosed
EP-1254897-A1 TRICYCLIC COMPOUNDS Ube Industries, Ltd. (JP) 2002-11-06 EP disclosed
EP-0685478-B1 QUINOLINE DERIVATIVES UBE INDUSTRIES (JP) 2001-10-24 EP disclosed
US-5591752-A LEUKOTRIENE ANTAGONIST, ANTIALLERGEN, ANTIINFLAMMATORY AGENT, DIBENZ(B,E)OXEPINE UBE INDUSTRIES, LTD. (JP) 1997-01-07 US disclosed
EP-0685478-A1 QUINOLINE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 1995-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216571-A1 Antiallergens; antiinflammatory agents CYSLTR2, CYSLTR1, LTC4S ALDH1A1 921/4885MAPT 4812/4885RAB9A 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.